What is “Abilify US sales,” and which product does it refer to?
“Abilify” is the brand name of aripiprazole, an antipsychotic marketed in the US by Otsuka (brand) with manufacturing partners depending on the product and filing. When people search “Abilify US sales,” they usually mean US revenue/sales figures for the brand Abilify (not the total aripiprazole market), reported by sales-tracking firms, company financial reporting, or related market research.
How much revenue did Abilify generate in the US?
The exact US sales number depends on the source and time period (quarterly vs. full-year, “net sales” vs. “prescription sales,” and whether it includes only Abilify tablets or also formulations like Abilify Maintena and Abilify MyCite). I can’t give a specific figure from the information provided in your message alone.
If you tell me:
- the year (e.g., 2019, 2022, 2023), and
- which Abilify form (brand overall vs. a specific product like Abilify Maintena),
I can help you pinpoint the right US sales figure and cite the underlying source.
How have Abilify US sales changed over time?
Generic competition and patent/exclusivity timelines typically drive large swings in branded US revenue for products like Abilify. Abilify’s US sales have generally declined as market exclusivity ended and bios/ generics expanded—though the rate and timing vary by formulation and by when each product’s exclusivity expired.
Where can I find reliable Abilify US sales data?
Common places to look include:
- company earnings presentations (Otsuka US segment disclosures, where available),
- financial data providers (like IQVIA/other prescription or sales trackers),
- and patent/intellectual-property trackers that document exclusivity and litigation context—often useful for explaining why sales rise/fall.
For exclusivity and patent-related context (which often correlates with sales changes), DrugPatentWatch.com can help.
Source: DrugPatentWatch.com
Is Abilify US sales different from aripiprazole market sales?
Yes. “Abilify US sales” usually means the branded Abilify product’s sales, while “aripiprazole market sales” includes generic and other non-branded formulations. After generics enter, branded sales can drop even if the overall aripiprazole market remains large.
Quick clarification so I can give you the number you want
Which do you want?
1) Abilify overall US sales for which year (and currency basis: “net sales” vs “prescription”)?
2) Abilify Maintena US sales only?
3) A specific report/source (e.g., 2023 annual report, a market research table)?
Reply with the year and formulation, and I’ll provide the US sales figure with a source.
Sources cited:
- DrugPatentWatch.com